{
  "id": "18807ba83aec8ad4",
  "title": "U . S . Food and Drug Administration ( FDA ) Approves Combination Treatment of VENCLEXTA\u00ae ( venetoclax ) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia ( CLL ) ",
  "description": "20260220T090000Z",
  "content": "",
  "source": "prnewswire.com",
  "source_url": "https://www.prnewswire.com/news-releases/us-food-and-drug-administration-fda-approves-combination-treatment-of-venclexta-venetoclax-and-acalabrutinib-for-previously-untreated-patients-with-chronic-lymphocytic-leukemia-cll-302693421.html",
  "published_at": "20260220T090000Z",
  "fetched_at": "2026-02-21T00:28:01.720640+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda",
    "drug"
  ],
  "location": "United States",
  "raw_data": {
    "url": "https://www.prnewswire.com/news-releases/us-food-and-drug-administration-fda-approves-combination-treatment-of-venclexta-venetoclax-and-acalabrutinib-for-previously-untreated-patients-with-chronic-lymphocytic-leukemia-cll-302693421.html",
    "url_mobile": "",
    "title": "U . S . Food and Drug Administration ( FDA ) Approves Combination Treatment of VENCLEXTA\u00ae ( venetoclax ) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia ( CLL ) ",
    "seendate": "20260220T090000Z",
    "socialimage": "",
    "domain": "prnewswire.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}